- Home
- ACXP vs PTIX Comparison
ACXP vs PTIX Comparison
Compare ACXP & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- PTIX
- Stock Information
- Founded
- ACXP 2017
- PTIX 1994
- Country
- ACXP United States
- PTIX United States
- Employees
- ACXP N/A
- PTIX N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- PTIX Health Care
- Exchange
- ACXP Nasdaq
- PTIX Nasdaq
- Market Cap
- ACXP 6.8M
- PTIX 6.3M
- IPO Year
- ACXP 2021
- PTIX 2016
- Fundamental
- Price
- ACXP $4.24
- PTIX $3.32
- Analyst Decision
- ACXP Strong Buy
- PTIX
- Analyst Count
- ACXP 3
- PTIX 0
- Target Price
- ACXP $143.67
- PTIX N/A
- AVG Volume (30 Days)
- ACXP 89.0K
- PTIX 109.1K
- Earning Date
- ACXP 11-12-2025
- PTIX 11-13-2025
- Dividend Yield
- ACXP N/A
- PTIX N/A
- EPS Growth
- ACXP N/A
- PTIX N/A
- EPS
- ACXP N/A
- PTIX N/A
- Revenue
- ACXP N/A
- PTIX N/A
- Revenue This Year
- ACXP N/A
- PTIX N/A
- Revenue Next Year
- ACXP N/A
- PTIX N/A
- P/E Ratio
- ACXP N/A
- PTIX N/A
- Revenue Growth
- ACXP N/A
- PTIX N/A
- 52 Week Low
- ACXP $3.80
- PTIX $2.25
- 52 Week High
- ACXP $43.20
- PTIX $15.26
- Technical
- Relative Strength Index (RSI)
- ACXP 51.39
- PTIX 44.99
- Support Level
- ACXP $3.97
- PTIX $3.22
- Resistance Level
- ACXP $4.85
- PTIX $3.53
- Average True Range (ATR)
- ACXP 0.35
- PTIX 0.31
- MACD
- ACXP -0.02
- PTIX -0.09
- Stochastic Oscillator
- ACXP 23.45
- PTIX 10.53
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.